三阴性乳腺癌新辅助化疗前后ki67变化及临床预后观察  

The Effect of ki67 on the Changes and Clinical Prognosis of Triple Negative Breast Cancer before and after Neoadjuvant Chemotherapy

作　　者：雷鸣 易朝锋[1] LEI Ming;YI Chaofeng(Department of Breast Surgery,Hengyang Maternal and Child Health Hospital,Hengyang City,Hu’nan Province 421001)

机构地区：[1]湖南省衡阳市妇幼保健院乳腺外科,421001

出　　处：《医学理论与实践》2020年第12期1914-1915,1921,共3页The Journal of Medical Theory and Practice

摘　　要：目的:探索ki67在三阴性乳腺癌新辅助化疗前后变化及临床预后的作用。方法:收集衡阳市妇幼保健院2013年1月-2014年12月间36例经病理确诊为三阴性乳腺癌患者,临床分期在ⅡB期及以上并进行新辅助化疗的乳腺癌患者免疫组化相关资料。结果:ki67在新辅助化疗后的表达明显下降,同时肿瘤组织分级、淋巴结缩小、肿块缩小有统计学差异,ki67下降率≥20%达到58.3%,同时总生存时间明显延迟。结论:ki67下降可作为一个评价新辅助化疗后乳腺癌患者预后的重要指标。Objective:To explore the effect of ki67 on the changes and clinical prognosis of triple negative breast cancer before and after neoadjuvant chemotherapy.Methods:From January 2013 to December 2014,36 cases of breast cancer diagnosed as triple negative by pathology with clinical stages ofⅡB or above and neoadjuvant chemotherapy were collected from Hengyang Maternal and Child Health Hospital.Results:The expression of ki67 decreased significantly after neoadjuvant chemotherapy.At the same time,there were statistical differences in tumor tissue classification,lymph node shrinkage and tumor shrinkage.The decrease rate of ki67≥20%reached 58.3%,while the total survival time was significantly delayed.Conclusion:ki67 decrease can be used as an important index to evaluate the prognosis of breast cancer patients after neoadjuvant chemotherapy.

关 键 词：三阴性乳腺癌 KI67 临床预后 

分 类 号：R737.9[医药卫生—肿瘤]